Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study

Conditions:   Cognitive Decline;   Intracerebral Hemorrhage;   Dementia, Vascular;   Cerebral Small Vessel Diseases;   Hypertension;   Stroke Hemorrhagic Interventions:   Drug: telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg;   Drug: Placebo oral capsule Sponsors:   The George Institute;   University of Sydney Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials